Efficacy and safety of regdanvimab in patients with mild/moderate COVID-19 and high risk of progression of the disease: a retrospective study in a short-term stay unit

Efficacy and safety of regdanvimab in patients with mild/moderate COVID-19 and high risk of progression of the disease: a retrospective study in a short-term stay unit

Background. The use of virus-neutralizing monoclonal antibodies is an effective method of etiotropic therapy for SARS-CoV-2 in patients of high-risk groups of severe COVID-19. Regdanvimab is a single-component monoclonal antibodies immunoglobulin G1, whose mechanism of action is aimed at binding SAR...

Full description

Bibliographic Details
Main Authors: Ulyana A. Markina, Daria S. Fomina, Marina S. Lebedkina, Tatiana S. Kruglova, Anton A. Chernov, Alena I. Zagrebneva, Zinaida Yu. Mutovina, Alexander V. Karaulov, Ekaterina I. Alexeeva, Mariana A. Lysenko
Format: Article
Language:Russian
Published: "Consilium Medicum" Publishing house 2022-06-01
Series:Терапевтический архив
Subjects:
covid-19
monoclonal antibodies
viral neutralizing antibodies
comorbidities
regdanvimab
omicron
Online Access:https://ter-arkhiv.ru/0040-3660/article/viewFile/108790/82904

Internet

https://ter-arkhiv.ru/0040-3660/article/viewFile/108790/82904

Similar Items